Otsuka and Lundbeck’s schizophrenia treatment gains EC approval
The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck’s Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment of schizophrenia. The treatment is indicated for use in adult schizophrenia patients who …